Harmony Biosciences reports Q4 net product revenue ~$168M, FY2023 ~$582M; 2024 guidance $700-720M

Harmony Biosciences Holdings, Inc.

2023-FY EPS reported $2.13 revenue$582,022,000

Preliminary Q4 net product revenue ~$168M, up ~31% YoY; FY2023 ~$582M, up ~33% YoY.
Average WAKIX patients ~6,150 in Q4 2023; 2024 target ~7,000 patients.
2024 net product revenue guidance of $700M to $720M.
Repurchased ~1.8M shares for $50M in Q4 2023; $150M remaining authorization.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Harmony Biosciences Holdings, Inc. reported 2024 results: revenue $700 million to $720 million. Guidance initiated.

Period: 2024
Revenue: $700 million to $720 million
Guidance: initiated
Result: guidance update

Exact text from the filing

Expect full year 2024 net product revenue of $700 million to $720 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Harmony Biosciences Holdings, Inc. reported the fourth quarter ended December 31, 2023 results: revenue approximately $168 million. Guidance raised.

Period: the fourth quarter ended December 31, 2023
Revenue: approximately $168 million
Guidance: raised
Result: preliminary results

Exact text from the filing

Preliminary, unaudited net product revenue for the quarter ended December 31, 2023, was approximately $168 million, compared to $128.3 million for the same period in 2022, representing ~31% growth

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Harmony Biosciences Holdings, Inc. reported the full year ended December 31, 2023 results: revenue approximately $582 million. Guidance raised.

Period: the full year ended December 31, 2023
Revenue: approximately $582 million
Guidance: raised
Result: preliminary results

Exact text from the filing

Preliminary, unaudited net product revenue for the full year ended December 31, 2023, was approximately $582 million, compared to $437.9 million for the same period in 2022, representing ~33% growth

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

Harmony Biosciences Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-000128

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.